There are currently 1290 clinical trials in Miami, Florida looking for participants to engage in research studies. Trials are conducted at various facilities, including University of Miami, GSK Investigational Site, University of Miami Miller School of Medicine-Sylvester Cancer Center and University of Miami Miller School of Medicine. Whether you're a healthy volunteer looking to participate in paid medical research or seeking trials related to a specific condition, the city provides a diverse range of opportunities near you.
Testing the Effect of M1774 on Hard-to-Treat Refractory SPOP-mutant Prostate Cancer
NCT05828082
Recruiting
This phase II trial tests how well M1774 works in treating patients with prostate cancer that does not respond to treatment (refractory) and that has a mutation in the gene responsible for making the speckle type BTB/POZ protein (SPOP). M1774 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Giving M1774 may be able to shrink or stabilize refractory SPOP-mutant prostate cancer.
Gender:
Male
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: University of Miami Miller School of Medicine-Sylvester Cancer Center, Miami, Florida
Conditions: Refractory Prostate Carcinoma
Register for Updates
A Study of Oral Tebipenem Pivoxil Hydrobromide (TBP-PI-HBr) Compared to Intravenous Imipenem-cilastatin in Participants With Complicated Urinary Tract Infection (cUTI) or Acute Pyelonephritis (AP)
NCT06059846
Recruiting
The primary purpose of this study is to assess the efficacy of oral TBP-PI-HBr as compared with intravenous (IV) imipenem-cilastatin with respect to the overall response (combined clinical cure plus microbiological eradication) at the Test-of-Cure (TOC) visit in hospitalized adult participants (≥18 years of age) with cUTI or AP.
Gender:
All
Ages:
18 years and above
Trial Updated:
06/11/2024
Locations: Medical facility, Miami, Florida
Conditions: Urinary Tract Infection, Acute Pyelonephritis
Register for Updates
A Study to Examine the Efficacy and Safety of Pozelimab and Cemdisiran Combination Therapy in Adult Patients With Symptomatic Generalized Myasthenia Gravis
NCT05070858
Recruiting
The primary objective is: To evaluate the effect of pozelimab + cemdisiran on daily functioning that is impacted by signs and symptoms in patients with symptomatic generalized myasthenia gravis (gMG) The secondary objectives of the study are: To evaluate the effect of pozelimab + cemdisiran (ie, combination) and cemdisiran monotherapy on: Clinician-assessed signs of myasthenia gravis (MG) and muscle strength Daily functioning that is impacted by signs and symptoms in patients with symptomati... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: Diverse Clinical Research, Miami, Florida
Conditions: Generalized Myasthenia Gravis
Register for Updates
A Study of Efficacy, Safety, and Tolerability of KAN-101 in People With Celiac Disease
NCT06001177
Recruiting
The study goal is to evaluate the efficacy, safety, and tolerability of KAN-101 in participants with Celiac Disease (CeD)
Gender:
All
Ages:
Between 18 years and 70 years
Trial Updated:
06/10/2024
Locations: Homestead Associates in Research Inc., Miami, Florida
Conditions: Celiac Disease, Coeliac Disease
Register for Updates
HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis
NCT06001385
Recruiting
The goal of this clinical trial is to determine the effectiveness of Reduced Dose Post-Transplant Cyclophosphamide (PTCy) in patients with hematologic malignancies after receiving an HLA-Mismatched Unrelated Donor (MMUD) . The main question[s] it aims to answer are: Does a reduced dose of PTCy reduce the occurrence of infections in the first 100 days after transplant? Does a reduced dose of PTCy maintain the same level of protection against Graft Versus Host Disease (GvHD) as the standard dose... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: University of Miami Sylvester Cancer Center, Miami, Florida
Conditions: Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myeloid Leukemia, Chronic Lymphocytic Leukemia, Myeloproliferative Neoplasm, Lymphoma, Chronic Myelomonocytic Leukemia, Pro-Lymphocytic Leukemia, Myelofibrosis
Register for Updates
A Study of BIIB067 (Tofersen) Initiated in Clinically Presymptomatic Adults With a Confirmed Superoxide Dismutase 1 Mutation
NCT04856982
Recruiting
The primary objective of this study is to evaluate the efficacy of tofersen in presymptomatic adult carriers of a superoxide dismutase 1 (SOD1) mutation with elevated neurofilament (NF). The secondary objectives of this study are to evaluate the safety and tolerability tofersen and to evaluate the effect of tofersen on pharmacodynamics (PD)/treatment response biomarkers when initiated prior to versus at the time of emergence of clinically manifest amyotrophic lateral sclerosis (ALS).
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: University of Miami, Miami, Florida
Conditions: Amyotrophic Lateral Sclerosis Associated With a SOD1 Gene Mutation
Register for Updates
A Study to Test BI 764198 in People With a Type of Kidney Disease Called Focal Segmental Glomerulosclerosis
NCT05213624
Recruiting
This study is open to adults with a type of kidney disease called focal segmental glomerulosclerosis (FSGS). The purpose of this study is to find out whether a medicine called BI 764198 improves the health of the kidneys in people with FSGS. Three different doses of BI 764198 are tested in this study. Participants are put into 4 groups randomly, which means by chance. Three of the groups receive different doses of BI 764198 and one group receives placebo. Participants are in the study for about... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: Total Research Group, LLC, Miami, Florida
Conditions: Kidney Disease, Chronic
Register for Updates
Efficacy and Safety of Pembrolizumab (MK-3475) in Combination With Bacillus Calmette-Guerin (BCG) in High-Risk Non-Muscle Invasive Bladder Cancer (HR NMIBC) (MK-3475-676/KEYNOTE-676)
NCT03711032
Recruiting
This study is designed to assess the antitumor efficacy and safety of pembrolizumab in combination with BCG, compared to BCG monotherapy, in participants with HR NMIBC that is either persistent or recurrent following adequate BCG induction (Cohort A), or that is naïve to BCG treatment (Cohort B). The primary hypothesis for Cohort A is that the combination of pembrolizumab plus BCG has a superior complete response rate (CRR) as assessed by central pathology review compared to BCG in participants... Read More
Gender:
All
Ages:
18 years and above
Trial Updated:
06/10/2024
Locations: University of Miami Hospital and Clinics, Sylvester Cancer Center ( Site 1056), Miami, Florida
Conditions: High-risk Non-muscle Invasive Bladder Cancer
Register for Updates
Study of Oral Atogepant When Added to OnabotulinumtoxinA (BOTOX) to Assess Adverse Events and Change in Disease Activity in Adult Participants With Chronic Migraine
NCT05216263
Recruiting
Migraine is characterized by attacks of throbbing, moderate or severe headache, often associated with nausea, vomiting, and/or sensitivity to light and/or sound. The study will assess safety and tolerability of atogepant when added to BOTOX, as well as prospectively evaluate the efficacy of add-on atogepant for migraine prevention. Adverse events and change in disease activity will be monitored. Atogepant is an investigational drug being developed to prevent chronic migraine. Approximately 75 a... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: University of Miami /ID# 252230, Miami, Florida
Conditions: Chronic Migraine
Register for Updates
Study to Check the Safety of Fazirsiran and Learn if Fazirsiran Can Help People With Liver Disease and Scarring (Fibrosis) Due to an Abnormal Version of Alpha-1 Antitrypsin Protein
NCT05677971
Recruiting
The main aim of this study is to learn if fazirsiran reduces liver scarring (fibrosis) compared to placebo. Other aims are to learn if fazirsiran slows down the disease worsening in the liver, to get information on how fazirsiran affects the body (called pharmacodynamics), to learn if fazirsiran reduces other liver injury (inflammation) and the abnormal Z-AAT protein in the liver, to get information on how the body processes fazirsiran (called pharmacokinetics), to test how well fazirsiran works... Read More
Gender:
All
Ages:
Between 18 years and 75 years
Trial Updated:
06/10/2024
Locations: Schiff Center for Liver Diseases/University of Miami, Miami, Florida
Conditions: Alpha1-Antitrypsin Deficiency
Register for Updates
A Study to Assess and Compare Safety and Tolerability of 3 Months Treatment With Salbutamol Administered Via MDI Containing Propellant HFA-152a or HFA-134a in Participants 12 Years of Age and Older With Asthma
NCT06261957
Recruiting
The goal of this study is to assess and compare the safety and tolerability of salbutamol administered via metered dose inhaler (MDI) containing propellant 1,1-difluoroethane (HFA-152a) or 1,1,1,2-tetrafluoroethane (HFA-134a) in participants aged 12 years and above with asthma.
Gender:
All
Ages:
12 years and above
Trial Updated:
06/10/2024
Locations: GSK Investigational Site, Miami, Florida
Conditions: Asthma
Register for Updates
A 24-Week Efficacy and Safety Study to Assess Budesonide and Formoterol Fumarate Metered Dose Inhaler in Adult and Adolescent Participants With Inadequately Controlled Asthma (VATHOS)
NCT05202262
Recruiting
This is a 24 week study to evaluate the efficacy and safety of budesonide and formoterol fumarate metered dose inhaler in adults and adolescents with inadequately controlled asthma.
Gender:
All
Ages:
Between 12 years and 80 years
Trial Updated:
06/10/2024
Locations: Research Site, Miami, Florida +3 locations
Conditions: Asthma
Register for Updates